QURE - uniQure N.V.
IEX Last Trade
17.12
0.120 0.701%
Share volume: 16,199
Last Updated: Fri 27 Dec 2024 04:30:11 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.12%
PREVIOUS CLOSE
CHG
CHG%
$17.00
0.12
0.71%
Fundamental analysis
18%
Profitability
2%
Dept financing
18%
Liquidity
75%
Performance
20%
Performance
5 Days
-0.46%
1 Month
186.78%
3 Months
248.74%
6 Months
294.32%
1 Year
147.86%
2 Year
-25.50%
Key data
Stock price
$17.12
DAY RANGE
$16.89 - $17.76
52 WEEK RANGE
$3.92 - $18.12
52 WEEK CHANGE
$154.03
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Matthew C. Kapusta
Region: US
Website: uniqure.com
Employees: 500
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: uniqure.com
Employees: 500
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
uniQure N.V. engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in clinical study for Huntington's disease.
Recent news